Why Novavax Stock Is Tumbling Today
Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be disappointed in the company's updates for both its experimental NanoFlu, and respiratory syncytial virus (RSV), vaccine candidates yesterday.
Image source: Getty Images.
Instead of the major clinical update some investors were expecting, Novavax simply noted, per its press release, that the ongoing late-stage RSV study in pregnant women remains on track for a mid-2018 interim analysis, and the company is accelerating enrollment to meet this target.
Source: Fool.com
Novavax Inc. Aktie
12,54 €
6,86 %
Leichtes Buy-Übergewicht bei Novavax Inc. mit 5 Buy- gegenüber 2 Sell-Einschätzungen.
Das Kursziel von 21 € für Novavax Inc. weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 12.54 € hin.
